Suppr超能文献

血糖控制和体重变化作为长期糖尿病患者胰腺癌早期标志物的潜力:一项病例对照研究。

The Potential of Glycemic Control and Body Weight Change as Early Markers for Pancreatic Cancer in Patients With Long-standing Diabetes Mellitus: A Case-Control Study.

作者信息

Mueller Alexandra M, Meier Christoph R, Jick Susan S, Schneider Cornelia

出版信息

Pancreas. 2018 Aug;47(7):807-815. doi: 10.1097/MPA.0000000000001085.

Abstract

OBJECTIVES

The aim of this study was to characterize the role of glycemic control and weight change as markers for pancreatic cancer (PaC) in patients with long-standing diabetes.

METHODS

We conducted case-control analyses in patients with long-standing diabetes (>2 years) in the United Kingdom-based Clinical Practice Research Datalink. Cases were patients with PaC matched to control subjects on variables including age, sex, and diabetes duration. We compared glycated hemoglobin (HbA1c) levels, blood glucose levels, and weight change before cancer detection (matched date) between cases and control subjects to assess associations between the potential markers and PaC.

RESULTS

Cases were more likely than control subjects to have high HbA1c levels. The adjusted odds ratio (aOR) was 4.94 (95% confidence interval [CI], 3.52-6.94) for HbA1c of 64.0 mmol/mol or greater compared with HbA1c of 47.5 mmol/mol or less within 6 months before cancer detection and within >1 to 2 years, 2.66 (95% CI, 2.00-3.54). Weight loss was also more common in cases, with an aOR of 15.40 (95% CI, 10.65-22.26) for loss of 15.0% body weight or greater compared with stable weight. The aOR for patients with both weight loss of 15.0% or greater and high HbA1c at 2 years or less before diagnosis was 60.97 (95% CI, 35.87-103.65), compared with patients with neither.

CONCLUSIONS

Poor glycemic control and weight loss, particularly in combination, may be useful early markers for PaC in patients with long-standing diabetes.

摘要

目的

本研究旨在明确血糖控制和体重变化作为长期糖尿病患者胰腺癌(PaC)标志物的作用。

方法

我们在英国临床实践研究数据链中对长期糖尿病(>2年)患者进行了病例对照分析。病例为胰腺癌患者,对照对象在年龄、性别和糖尿病病程等变量上与病例匹配。我们比较了病例组和对照组在癌症检测前(匹配日期)的糖化血红蛋白(HbA1c)水平、血糖水平和体重变化,以评估潜在标志物与胰腺癌之间的关联。

结果

病例组的HbA1c水平高于对照组。在癌症检测前6个月内且在>1至2年内,HbA1c为64.0 mmol/mol或更高与HbA1c为47.5 mmol/mol或更低相比,校正优势比(aOR)为4.94(95%置信区间[CI],3.52 - 6.94);在癌症检测前>1至2年内,aOR为2.66(95% CI,2.00 - 3.54)。体重减轻在病例组中也更常见,体重减轻15.0%或更多与体重稳定相比,aOR为15.40(95% CI,10.65 - 22.26)。诊断前2年或更短时间内体重减轻15.0%或更多且HbA1c高的患者与两者均无的患者相比,aOR为60.97(95% CI,35.87 - 103.65)。

结论

血糖控制不佳和体重减轻,尤其是两者同时出现,可能是长期糖尿病患者胰腺癌的有用早期标志物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验